Vagus Nerve Stimulation for Chronic Widespread Pain

This study is looking at how stimulating a nerve called the vagus nerve might help adults with chronic widespread pain or fibromyalgia. Researchers want to see if two different ways of stimulating this nerve—either through deep breathing exercises (deep exhalation) or with a small electrical device placed on the ear (ear electrical stimulation)—can reduce pain intensity, muscle stiffness, and improve overall well-being. The study aims to find out if vagus nerve stimulation helps with pain and which method might be more effective. You could be eligible if you are an adult aged 18 or older with a diagnosis of chronic widespread pain or fibromyalgia, but not if you have certain heart or nerve conditions.

Study design
This is a randomized controlled study planning to enroll 100 participants. It will compare two types of vagus nerve stimulation with a group that receives no immediate treatment.
What's involved
Participants will either perform deep exhalation exercises, use an ear electrical stimulator, or be in a group that receives no treatment for two weeks. Pain intensity will be measured at two weeks, and muscle stiffness at eight weeks.
Compensation
Not stated in the trial record.
Follow-up
Pain intensity is measured from enrollment to the end of treatment at 2 weeks, and muscle stiffness is measured from enrollment to the end of treatment at 8 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07080749

The Effect of Vagus Nerve Stimulation on Pain and Functional Activities in Individuals With Chronic Widespread Pain

Not Yet Recruiting
NAAges 18+InterventionalTreatment
University of North Georgia
~100 participants
Updated 2025-07-23 on ClinicalTrials.gov
What's tested:Vagal nerve stimulation through deep exhalation exerciseVagal nerve stimulation through ear electrical stimulationNo intervention (observational study)

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Pain Intensity
Measured over From enrollment to the end of treatment at 2 weeks
+15 more outcomes measured
Widspread Chronic Pain, Fibromyalgia
1 sites across 1 states
Georgia1
Mohammad Reza Nourbakhsh, PT, Ph.D.
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

  • Pain IntensityFrom enrollment to the end of treatment at 2 weeks

    Pain intensity will be assessed using the Visual Analog Scale (VAS), a 10 cm horizontal line anchored by "no pain" and "worst imaginable pain." Participants mark their current level of pain on the line, which is measured in centimeters (cm).

  • Muscle stiffnessFrome enrollment to the end of treatment at 8 weeks

    Muscle stiffness, defined as the resistance of the tissue to an external force, will be measured in the upper trapezius using the MyotonPro device. Stiffness reflects the biomechanical integrity of muscle tissue. Unit of Measure: Newtons per meter (N/m)

  • Pressure Pain Threshold - Trapezius muscleFrom enrollment to the end of treatment period at 2 weeks

    Pressure pain threshold (PPT) at the mid-belly of the upper trapezius will be assessed using a calibrated analog pressure algometer. PPT is defined as the minimum force required to elicit pain and reflects mechanical pain sensitivity. Unit of Measure: Kilograms per square centimeter (kg/cm²).

  • SDNN (Standard Deviation of NN intervals)From enrollment to the end of treatment at 2 weeks

    SDNN will be used to assess overall heart rate variability, reflecting both sympathetic and parasympathetic nervous system activity over a 10-minute resting period. Unit of Measure: milliseconds (ms).

  • Mechanical Stress Relaxation TimeFrom enrollment to the end of treatment at 8 weeks

    Mechanical Stress Relaxation Time, defined as the time required for tissue to return to its original state following a mechanical impulse, will be measured using the MyotonPro device. This parameter reflects the viscoelastic properties of skeletal muscle. Unit of Measure: milliseconds (ms).

  • Muscle Oscillation FrequencyFrom enrollment to the end of treatment at 8 weeks.

    Frequency, representing the natural oscillation frequency of muscle tissue in response to a brief mechanical impulse, will be measured using the MyotonPro device. It reflects the intrinsic muscle tone and biomechanical behavior of the tissue. Unit of Measure: Hertz (Hz).

  • Pressure Pain Threshold - Lumbar Paraspinal MusclesFrom enrollment to the end of treatment at 8 weeks

    PPT at the lumbar paraspinal region (L5 level) will be measured using an analog pressure algometer to assess localized pain sensitivity. Unit of measurement: Kilograms per square centimeter (kg/cm²)

  • Pressure Pain Threshold - Calf MusclesFrom enrollment to the end of treatment at 8 weeks

    PPT at the junction of the gastrocnemius and soleus muscles in the calf will be measured using a pressure algometer to evaluate distal pain sensitivity. Unit of Measure: Kilograms per square centimeter (kg/cm²)

  • Muscle Elasticity (Logarithmic Decrement)From enrollment to the end of treatment at 8 weeks

    Elasticity, measured as logarithmic decrement, describes the ability of muscle tissue to return to its original shape after deformation. It will be measured using the MyotonPro on the upper trapezius. Lower values indicate greater elasticity. Unit of Measure: Unitless (logarithmic decrement)

  • RMSSD (Root Mean Square of Successive Differences)Baseline, after 2 weeks and after 8 weeks

    RMSSD will be used as a marker of short-term parasympathetic activity. Unit of Measure: milliseconds (ms).

  • SDANN (Standard Deviation of Average NN intervals)Baseline, after 2 weeks, and after 8 weeks

    SDANN will be used to evaluate longer-term components of heart rate variability associated with sympathetic activity. Unit of Measure: milliseconds (ms)

  • LF Power (Low Frequency Power)Baseline, after 2 weeks and after 8 weeks

    LF Power will be analyzed to assess contributions from both sympathetic and parasympathetic nervous systems in frequency domain. Unit of Measure: milliseconds² (ms²).

  • HF Power (High Frequency Power)Baseline, after 2 weeks and after 8 weeks

    HF Power will be measured to evaluate parasympathetic (vagal) nervous system activity. Unit of Measure: milliseconds² (ms²).

  • LF/HF RatioBaseline, after 2 weeks and after 8 weeks

    LF/HF ratio will be used as a marker of autonomic balance, indicating the relative influence of sympathetic to parasympathetic tone. Unit of Measure: Ratio (unitless).

  • VLF Power (Very Low Frequency Power)Baseline, after 2 weeks and after 8 weeks

    VLF Power will be measured to assess longer-term regulatory systems, including thermoregulation and hormonal factors. Unit of Measure: milliseconds² (ms²).

  • ULF Power (Ultra Low Frequency Power)Baseline, after 2 weeks and after 8 weeks

    ULF Power will be assessed to capture circadian and ultradian influences on autonomic regulation. Unit of Measure: milliseconds² (ms²).